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Abstract
Introduction: Conventional cancer registries are suitable for simple surveillance
of cancer patients, including disease frequency and distribution, demographics,
and prognosis; however, the collected data are inadequate to clarify comprehen-
sively diverse clinical questions in daily practice.
Methods: We constructed an umbrella-type lung cancer patient registry (CS-Lung-
003) integrating multiple related prospective observational studies (linked studies)
that reflect clinical questions about lung cancer treatment. The primary endpoint of
this registry is to clarify daily clinical practice patterns in lung cancer treatment; a
key inclusion criterion is pathologically diagnosed lung cancer. Under this registry,
indispensable clinical items are detected in advance across all active linked studies
and gathered prospectively and systematically to avoid excessive or insufficient data
collection. Researchers are to input information mutually, irrespective of the rele-
vance to each researcher’s own study. Linked studies under the umbrella of the CS-
Lung-003 registry will be updated annually with newly raised clinical questions;
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some linked studies will be newly created, while others will be deleted after the com-
pletion of the analysis. Enrollment began in July 2017.
Discussion: We successfully launched the umbrella-type CS-Lung-003 registry.
Under this single registry, researchers collaborate on patient registration and data
provision for their own and other studies. Thus, the registry will produce results
for multiple domains of study, providing answers to questions about lung cancer
treatment raised by other researchers. Through such analysis of each linked
study, this registry will contribute to the comprehensive elucidation of actual
daily practice patterns in lung cancer treatment.
Key points
• CS-Lung-003 registry directly integrates multiple linked studies created under
the umbrella of this cancer registry to solve various clinical questions regard-
ing daily practice patterns of lung cancer treatment.
Introduction
The results of many pivotal lung cancer clinical trials can
be used to update treatment guidelines leading to improved
daily practice. However, many real-world clinical questions
remain. To clarify these questions, it is indispensable to
collect relevant information on clinical practices and ana-
lyze these data comprehensively; this real-world data analy-
sis of practice patterns will provide clues to current clinical
questions and also lead to the creation of new meaningful
clinical questions further improving daily treatment.
In recent years, large-scale cancer registries for patient sur-
veillance have been constructed worldwide.1 We also created
a registry of 1000 patients with lung cancer in one and a half
years to clarify the characteristics of a subpopulation with
HER2-positive tumors.2–4 In most situations, existing cancer
registry data are best used for relevant observational studies
that researchers newly plan and conduct with the primary
purpose of answering their own clinical questions; thus,
almost all these observational studies are retrospective. These
studies are valuable as they clarify clinical practice patterns
for cancer treatment, actual safety data and quantification of
potential risks, and the effectiveness of therapeutics involving
a broader patient population within a community-based set-
ting compared to randomized clinical trials.
However, the patient information contained in conven-
tional cancer registries is monotonous, repetitive, static, and
limited. In contrast, clinical questions raised by clinicians in
their daily practice are complicated, dynamic, and subject to
change. Thus, conventional cancer registries are inadequate
for data analysis to address such clinical questions appropri-
ately and timeously.5 Specifically, the biggest disadvantage of
conventional cancer registries is that data on many clinical
items are usually collected in an unfocused manner, without
any insight beforehand as to what kind of clinical information
is truly needed for relevant observational studies. Therefore,
conventional cancer registries may be lacking in specific items
for some researchers or may collect unnecessary or excessive
items for others.6,7 Ultimately, conventional cancer registries
are suitable for simple surveillance of cancer patients; how-
ever, these registries lack efficient processes for data collection
to clarify multiple researchers’ clinical questions as they are
not specifically designed and constructed to address such
questions (Fig 1).
In this article, we introduce a unique, umbrella-type lung
cancer patient registry equipped with multiple related prospec-
tive observational studies created in accordance with assorted
concrete clinical questions; this novel registry will solve the
above-mentioned problems with existing registry studies.
Methods
The CS-Lung-003 is a new prospective lung cancer patient
registry compiled by 29 hospitals that provide lung cancer
treatment in Chugoku and Shikoku regions in western
Japan. This study was registered on 25 March 2017 with
UMIN-CTR Clinical Trial as UMIN000026696. As a
unique feature of this registry, it integrates multiple studies
from related fields (Table 1; Fig 1, 2). We use the term
“linked study” which means one that falls in a related field
of this CS-Lung-003 cancer registry study. These linked
studies must fulfill all the following conditions: (i) Each are
to be conducted as a prospective observational study;
(ii) their common target population is to be pathologically
diagnosed lung cancer patients; and (iii) their study objec-
tive is determined according to each study, with a mini-
mum shared commonality regarding the clarification of
some patterns of daily clinical practices. The latter two condi-
tions have also been set as the eligibility criteria and the
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comprehensive primary endpoint of the CS-Lung-003 cancer
registry study coordinating each of the linked studies, respec-
tively. Notably, related studies under the umbrella of the CS-
Lung-003 cancer registry are updated annually in response to
the latest clinical questions that arise subsequent to the release
of new evidence and guidelines; some of the linked studies
will be newly created and linked to this CS-Lung-003 cancer
registry and others deleted after the completion of their analy-
sis. The ethical validity of the updated registry is to be con-
firmed by the institutional review board each time.
This registry uses REDCap (Vanderbilt University, TN,
USA) as an electronic data capture system, the operation of
which is outsourced.8 REDCap is a data collection and man-
agement system, allowing any clinicians without any IT
expertise, to easily build and manage databases on the Web,
and to easily and safely collect data from multiple facilities.
In this study, clinical items necessary for each linked study
proposed by investigators based on their clinical questions,
are reflected into the REDCap EDC system. At first, under
this registry, key variables (sex, birth month/year, ECOG-
PS, tissue type, TNM, stage, pathological diagnosis date, last
survival confirmation date and death or survival) and any
truly indispensable clinical items to be collected prospec-
tively for the analysis in each linked study are surveyed in
advance and identified across all active linked studies. The
detected items are displayed directly on the data entry
screen of the electronic data capture system of the CS-Lung-
003, the main cancer registry, while excluding duplicated
items across the linked studies. Researchers are to input all
these items, irrespective of their relevance to each
researcher’s own study. All these processes enable the regis-
try to gather relevant data systematically and efficiently. At
the time of analysis in each linked study, the entire registry
dataset will be processed. Furthermore, the data entry screen
in the CS-Lung-003 will be modified annually along with an
update of the linked studies, always capturing all the clinical
items across the active studies and excluding duplicated
items to avoid excessive or insufficient data collection.
Figure 1 Conceptual diagram of CS-Lung-003. Existing cancer registries are suitable for simple surveillance of patients with cancer and are generally
designed to collect relevant clinical items widely and superficially for analyses. Therefore, they are not specifically designed and constructed according to
daily clinical questions raised by researchers. As a result, when planning to use these registry databases for analyses in their own studies, certain required
items may be lacking for some researchers which might cause failure at the analytic stage of their study (ie, Study C). *Each linked study must fulfill all
the following conditions: (i) Each are to be conducted as a prospective observational study; (ii) their common target population is to be pathologically
diagnosed lung cancer patients; and (iii) their study objective is determined according to each study, with a minimum shared commonality regarding
the clarification of some patterns of daily clinical practices. The latter two conditions have also been set as the eligibility criterium and the comprehensive
primary endpoint of the CS-Lung-003 cancer registry study coordinating each of the linked studies, respectively. **The detected indispensable clinical
items are reflected directly in the case report form of CS-Lung-003, the main cancer registry, while excluding duplicated items across the linked studies.
***Researchers are to input all these items, irrespective of their relevance to each researcher’s own study. All these processes enable the registry to
gather data systematically and efficiently. #At the time of analysis in each linked study, the entire registry dataset will be processed.
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Table 1 Linked studies integrated in this registry study (excerpt)
Year Study title Endpoints
2017 Dissemination of short-term low-volume
hydration in patients with cisplatin-based
chemotherapy
Proportion of patients with the hydration
method; Cr toxicity stratified by the
method; other AE
Survey on undertreated advanced lung
cancer in the elderly
Proportion of those with anticancer
treatment; treatment compliance; AE;
survival
Characteristics and outcome of SCLC
patients without any smoking history
Proportion of non-smokers in patients with
SCLC; presence of occupational risk
factors; stage distribution; treatment
regimen and compliance; AE; survival
Implementation of rebiopsy for recurrent
NSCLC harboring EGFR mutations
Rebiopsy rate at the time of failure with first-
or second-generation EGFR-TKI; T790M-
positive rate; frequency of osimertinib use
and its efficacy; repeated rebiopsy rate in
those with T790M-negative results from
the first rebiopsy
Survey on early line of treatment in ED-SCLC Type and pattern of treatment regimens;
PFS; OS; AE
Characteristics and outcome of progressive
high-grade pulmonary neuroendocrine
tumor
Clinical demographics; type and pattern of
treatment; ORR; PFS; OS; AE
Survey on early line of treatment in EGFR-
mutant; advanced NSCLC
Type and pattern of treatment regimens;
PFS; OS; AE
Effect of severity in comorbid COPD on
treatment compliance
Frequency of COPD and its severity; type and
pattern of treatment; treatment
compliance; PFS; OS; AE
Influence of timing of prior ICI use on EGFR-
TKI-related AEs
Incidence of grade ≥3 AEs in EGFR-TKI
therapy; its association with prior ICI use;
efficacy of EGFR-TKI and its association
with prior ICI use
Characteristics and outcome of advanced
pulmonary polymorphic cancer
Clinical demographics; type and pattern of
treatment; ORR; PFS; OS
Association of strictness in management of
diabetes on outcomes in lung cancer
Type and pattern of DM treatment; time
course of HbA1C and its association with
frequency of acute exacerbation of DM
and lung cancer survival
Recent trend of incidence, treatment, and
mortality of febrile neutropenia occurring
in the treatment of advanced lung cancer
FN rate; type and pattern of its treatment;
treatment outcome; association of FN
event with PFS and OS
Dissemination of early palliative care team
intervention in clinical practices and its
survival impact in the lung cancer
treatment
Frequency of intervention by the team;
association of the intervention with OS
2018 Real-world data analysis on epidemiology,
treatment, and prognosis of central nerve
system lesions in non-small cell lung
cancer patients
Clinical characteristics; type and pattern of
treatment; ORR; CNS-ORR; PFS; CNS-PFS;
OS; AE
Implementation of ramucirumab use in
combination with docetaxel in clinical
practices in relapsed non-small cell lung
cancer
Implementation rate of ramucirumab in
combination with docetaxel; reasons why
not administered
The relationship of the localization of
primary lung cancer to the response and
survival outcome of ICI
Association between primary tumor location
and OS
Clinical features of lung cancer complicated
with polymyositis/dermatomyositis
Clinical characteristics; treatment outcome
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Approximately 2000 patients with lung cancer will be
accrued in the CS-Lung-003 cancer registry, whilst the number
of required cases is calculated per linked study according to its
own primary endpoint. The study period has been set from
March 2017 to March 2029. After the linked study has been
completed, the case records for the linked study are properly
discarded. The entire database will be retained for 10 years
after all the proposed linked studies have been completed.
The study protocol was approved by the Okayama Uni-
versity Hospital Ethics Committee (approval No. 1703–055)
and the institutional review boards of each participating
hospital. Written informed consent was obtained from
each patient prior to any registration for the study. This
study is performed in accordance with the Declaration of
Helsinki and the relevant Japanese regulations.
Discussion
The most remarkable feature of this CS-Lung-003
community-based registry study is that it is an umbrella-
type study; it directly integrates multiple linked studies cre-
ated under the umbrella of this cancer registry to solve var-
ious clinical questions regarding daily practice patterns of
lung cancer treatment. Moreover, each linked study related
to the main CS-Lung-003 cancer registry is designed in a
prospective fashion. In most prior master protocols, the
registry data, although collected prospectively, were com-
piled post hoc for relevant retrospective cohort studies9;
our study structure for the prospective registry involving
related prospective observational studies enables us to
eliminate biases more effectively, including patient selec-
tion bias that occurs mostly in retrospective cohort
studies.10
Another unique feature of this registry study design is
the “implementation of mutative collaboration,” that is,
researchers will collect clinical items for their own analysis
as the principal investigator in their linked study. Simulta-
neously, they will also act as coinvestigators for other
items, whether the items are relevant to their own study or
not. This structure could provide a scale of merit for each
Table 1 Continued
Year Study title Endpoints
PD-L1 expression and implementation of ICI
use in clinical practices in driver oncogene-
positive non-small cell lung cancer
Proportions of positive PD-L1 expression level
and ICI use
Clinical influence of a palliative radiotherapy
on the effect of ICI in non-small cell lung
cancer
ORR; PFS; OS; AE; association of type and
pattern of radiotherapy with efficacy
and safety
Implementation rate, safety and efficacy of
ICI in lung cancer with interstitial
pneumonia
Type and regimen of ICI treatment; ORR;
acute exacerbation rate; TTF; OS; AE
2019 Implementation of ICI use and outcome in
stage III NSCLC after completion of
chemoradiotherapy
Proportion of ICI use in NSCLC patients after
completion of chemoradiotherapy; AE;
ORR; PFS; OS
Dissemination of chemoimmunotherapy in
the first-line setting in driver-negative,
advanced non-small cell lung cancer
Proportion of those receiving first-line
chemoimmunotherapy; AE; ORR; PFS; OS
Recent incidence of thromboembolism, its
treatment types and prognosis in
advanced lung cancer patients
Incidence of comorbid thromboembolism
at the initial presentation; occurrence
rate of developing symptomatic/
asymptomatic thromboembolism after
lung cancer diagnosis; survival stratified
by the presence thromboembolism
Occurrence of hepatitis B in HBV-careered or
prior HBV-infected patients with lung
cancer receiving ICI treatment
Occurrence rate of hepatitis B; other AEs;
type and pattern for preventive
treatment of hepatitis; ORR; PFS; OS
Implementation of ICI use in NSCLC patients
with autoimmune diseases and their
treatment outcome
Proportion of those receiving ICI therapy;
type and severity of autoimmune
disease and its association with AE;
ORR; PFS; OS
AE, adverse event; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; Cr, creatinine; DM, diabetes mellitus; ED, extensive
disease; EGFR, epidermal growth factor receptor; FN, febrile neutropenia; HBV, hepatitis B virus; ICI, immune checkpoint inhibitor; NSCLC, non-small
cell lung cancer; ORR, overall response rate; OS, overall survival; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; SCLC, small
cell lung cancer; TKI, tyrosine kinase inhibitor; TTF, time to treatment failure.
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linked study since its targeted patients are to be recruited
not by a single institute but by multiple institutes affiliated
with the CS-Lung-003 cancer registry. Finally, such func-
tional collaboration can increase the motivation for becom-
ing involved in the registry study, leading to the potential
sustainability of this registry.
The issue of gathering more or less data than required
for proceeding with the planned analysis has been raised in
most registry studies.5 This is mainly because most cancer
registries are intended for patient surveillance only and
gather general clinical items without any prior consider-
ation for addressing various clinical questions. Regarding
our registry, to avoid excessive or insufficient data collec-
tion, we attempt to detect any indispensable items to be
collected in advance across all the active linked studies
involved in the CS-Lung-003 cancer registry. The prospec-
tive nature of each linked study enables this process to be
guaranteed resulting in maximally efficient data collection
in our registry. Thus, our registry is a breakthrough regard-
ing solving the above-mentioned issue.
Our platform also appears to have an advantage regard-
ing ethical issues. In the case of retrospective master proto-
col registry studies, the ethics of its entire framework can
be confirmed by an ethical review board. However, it has
been pointed out that each linked study is lacking in ethi-
cal compliance, because these studies are created after the
master protocol has been launched, and, thus, are not
examined by the review committee.5 In contrast, we can
ensure ethical compliance by annually submitting changes
in the protocol body of the CS-Lung-003 cancer registry
study that lists the latest linked studies. The limitation of
this study is that we do not strictly check all pathologically
diagnosed lung cancer patients have been registered, poten-
tially affecting the results of causal relationship in each
linked study.
In summary, we have successfully launched an
umbrella-type lung cancer registry (CS-Lung-003) that
integrates diverse prospective observational studies
reflecting various daily clinical questions. Under this single
registry, researchers can mutually resolve their clinical
questions, collaborate on patient registration and data pro-
vision for their own study and those of other researchers.
This CS-Lung-003 cancer registry has several unique fea-
tures and will solve various problems with existing registry
studies; it is expected to produce multiple linked studies,
and provide answers to the clinical questions about lung
cancer treatment raised by researchers. These outcomes
may result in further comprehensive understanding and
awareness of daily practices of lung cancer treatment,
potentially leading to behavioral changes regarding
researchers’ treatment strategies.
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